Iloperidone

CHEMBL14376 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

426.5 g/mol

LogP

4.1

Phase

4

This atypical antipsychotic is used to treat schizophrenia in adults and works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. It is associated with a lower incidence of extrapyramidal side effects compared to older antipsychotics. QTc prolongation (a heart rhythm change) is an important consideration, requiring cardiac monitoring in some patients.

分子量

426.5000 g/mol

LogP

4.10

TPSA

64.80 Å²

リピンスキーの五則

適合

治療領域

Schizophrenia Bipolar Disorder Stroke Hypertension Major Depressive Disorder

作用機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1

InChI

InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3

Molecular Formula

C24H27FN2O4

HBD / HBA

- / 7

回転可能結合数

8

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This atypical antipsychotic is used to treat schizophrenia in adults and works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. It is associated with a lower incidence of extrapyramidal side effects compared to older antipsychotics. QTc prolongation (a heart rhythm change) is an important consideration, requiring cardiac monitoring in some patients.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Iloperidone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14376. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71360. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Iloperidone PillFYIで

構造

クイックデータ

分子式: C24H27FN2O4
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.